BridgeMD
New treatment option for Heart Failure With Reduced Ejection Fraction
Official title Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
ClinicalTrials.gov ID: NCT06526988
What this study is testing
- What it's testing
- An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF). When used in combination at recommended doses, patients often experience significant improvements in cardiac function, quality of life, and survival.1,2 However, GDMT underuse occurs for the vast majority of patients with HFrEF.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Clinician:
- Clinician (MD, PA, NP) who practices in cardiology outpatient clinics
- Regularly sees patients with left ventricular ejection fraction (EF) \</=40%, where their panel of patients over the last year included at least 10...
- Age \> 18 years
- LVEF \</=40% on most recent cardiology imaging study
You likely can't join if
- Patient:
- Has a left ventricular assist device
- Under evaluation for or listed for transplant (or s/p transplant)
- Glomerular filtration rate (GFR) less than 20 or on dialysis
- On hospice care
- Preferred language neither English or Spanish
See the full eligibility criteria
- Clinician:
- Clinician (MD, PA, NP) who practices in cardiology outpatient clinics
- Regularly sees patients with left ventricular ejection fraction (EF) \</=40%, where their panel of patients over the last year included at least 10 patients with heart failure with reduced ejection fraction (HFrEF)...
- Age \> 18 years
- LVEF \</=40% on most recent cardiology imaging study
- Has a new or return clinic visit with an enrolled clinician within the next 7 days
- Is missing at least one of the four classes of medications and does not have an allergy to that class: (1) beta blockers, (2) angiotensin receptor-neprilysin inhibitor, (3) aldosterone receptor antagonists, (4)...
- Patient:
- Has a left ventricular assist device
- Under evaluation for or listed for transplant (or s/p transplant)
- Glomerular filtration rate (GFR) less than 20 or on dialysis
- On hospice care
- Preferred language neither English or Spanish
The study team makes the final eligibility decision.
Where it's taking place
- Walnut Creek, California, United States
- Aurora, Colorado, United States
- New Haven, Connecticut, United States
- Chicago, Illinois, United States
- Salt Lake City, Utah, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Walnut Creek, California, United States; Aurora, Colorado, United States; New Haven, Connecticut, United States; Chicago, Illinois, United States; Salt Lake City, Utah, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.